Trial Profile
Vorapaxar in the Human Endotoxemia Model A Randomized, Double-Blind, Crossover Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Vorapaxar (Primary)
- Indications Arterial thrombosis; Blood coagulation disorders; Inflammation
- Focus Therapeutic Use
- 04 Jun 2018 Primary endpoint (Changes in Prothrombin fragments F1+2:vorapaxar versus placebo) has been met, according to results published in the Thrombosis and Haemostasis Journal.
- 04 Jun 2018 Results published in the Thrombosis and Haemostasis Journal.
- 27 Mar 2017 Status changed from recruiting to completed.